Showing results (101-110 of 159) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2023
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AMLKeith W Pratz, Mohamad Cherry, Jessica K Altman, et al.
Blood|September 13, 2003
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cellsRui Zheng, Mark Levis, Obdulio Piloto, et al.
Leukemia Research|September 26, 2021
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemiaHetty E Carraway, Yazeed Sawalha, Ivana Gojo, et al.
Cancer Research|March 1, 2005
Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient miceObdulio Piloto, Mark Levis, David Huso, et al.
Leukemia Research|August 2, 2011
A potential therapeutic target for FLT3-ITD AML: PIM1 kinaseAmir T Fathi, Omotayo Arowojolu, Ian Swinnen, et al.
American Journal of Hematology|December 23, 2014
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndromePaolo Strati, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia|May 29, 2024
Inhibition of NOTCH4 sensitizes FLT3/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibitionRuiqi Zhu, Courtney M Shirley, S Haihua Chu, et al.
Transplantation and Cellular Therapy|November 6, 2022
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid MalignanciesMatthew P Connor, Alison W Loren, Elizabeth O Hexner, et al.
Blood Advances|January 31, 2025
Evolving racial/ethnic disparities in AML survival in the novel therapy eraXin Wang, Phyllis A Gimotty, Andrew H Matthews, et al.
Blood Advances|September 8, 2018
Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamideLaura K Schoch, Kenneth R Cooke, Nina D Wagner-Johnston, et al.
Pageof 16